Literature DB >> 33102178

Conduction disorders after aortic valve replacement with rapid-deployment bioprostheses: early occurrence and one-year evolution.

Augusto D'Onofrio1, Chiara Tessari1, Lorenzo Bagozzi1, Federico Migliore1, Claudia Filippini2, Giorgia Cibin1, Rita Pesce1, Annalisa Francescato1, Gino Gerosa1.   

Abstract

BACKGROUND: Rapid-deployment bioprostheses represent one of the newest aortic valve substitutes introduced into clinical practice. The aim of this retrospective single-center study was to evaluate the occurrence of conduction disorders (CDs) after rapid-deployment aortic valve implantation at discharge and at 1-year follow-up, and to identify risk factors for CDs and permanent pacemaker implantation (PPI).
METHODS: All patients who reached 1-year follow-up after isolated or combined aortic valve replacement (AVR) with rapid-deployment bioprostheses (Intuity Elite, Edwards Lifesciences, Irvine, CA) at our institution were included in this study. Standard 12-lead electrocardiograms (ECGs) were recorded before the procedure (within 24 hours), after the procedure as soon as the patient was moved to the intensive care unit (ICU), every day during in-hospital stay and at 1-year follow-up. The primary endpoint was the incidence of postoperative CDs at discharge and at 1-year follow up. Patients were divided in two groups: those who developed the primary endpoint (Group CD) and those who didn't (Group Non-CD).
RESULTS: A total of 98 consecutive patients were included in the study. At discharge, the primary endpoint occurred in 40 patients (40.8%). In particular, new CDs and PPI occurred in 33 (33.7%) and in 7 (7.1%) patients, respectively. Valve size was the only independent predictor of primary endpoint at discharge. At 1-year, 30 patients (31.3%) presented with CDs or pacemaker-induced rhythm. In particular, in 25 patients of Group CD (64.1%), 1-year follow-up ECG revealed the persistence of the same CD as at discharge or pacemaker-induced rhythm, while 14 patients (35.9%) showed recovery of their CD. Age and prosthesis size were identified as independent predictors of CDs/pacemaker-induced rhythm at 1-year follow-up.
CONCLUSIONS: According to our data, nearly 40% of patients develop a new CD after rapid-deployment aortic valve implantation. Of these, one third recover after one year. Bioprosthesis size and age were identified as independent risk factors for occurrence of CD after surgery. 2020 Annals of Cardiothoracic Surgery. All rights reserved.

Entities:  

Keywords:  Aortic valve replacement (AVR); conduction disorders (CDs); heart valve prosthesis; pacemaker; rapid deployment; sutureless

Year:  2020        PMID: 33102178      PMCID: PMC7548210          DOI: 10.21037/acs-2020-surd-14

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN: 2225-319X


  21 in total

1.  EuroSCORE II.

Authors:  Samer A M Nashef; François Roques; Linda D Sharples; Johan Nilsson; Christopher Smith; Antony R Goldstone; Ulf Lockowandt
Journal:  Eur J Cardiothorac Surg       Date:  2012-02-29       Impact factor: 4.191

Review 2.  AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology.

Authors:  Borys Surawicz; Rory Childers; Barbara J Deal; Leonard S Gettes; James J Bailey; Anton Gorgels; E William Hancock; Mark Josephson; Paul Kligfield; Jan A Kors; Peter Macfarlane; Jay W Mason; David M Mirvis; Peter Okin; Olle Pahlm; Pentti M Rautaharju; Gerard van Herpen; Galen S Wagner; Hein Wellens
Journal:  J Am Coll Cardiol       Date:  2009-03-17       Impact factor: 24.094

3.  2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA).

Authors:  Michele Brignole; Angelo Auricchio; Gonzalo Baron-Esquivias; Pierre Bordachar; Giuseppe Boriani; Ole-A Breithardt; John Cleland; Jean-Claude Deharo; Victoria Delgado; Perry M Elliott; Bulent Gorenek; Carsten W Israel; Christophe Leclercq; Cecilia Linde; Lluís Mont; Luigi Padeletti; Richard Sutton; Panos E Vardas; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Paulus Kirchhof; Carina Blomstrom-Lundqvist; Luigi P Badano; Farid Aliyev; Dietmar Bänsch; Helmut Baumgartner; Walid Bsata; Peter Buser; Philippe Charron; Jean-Claude Daubert; Dan Dobreanu; Svein Faerestrand; David Hasdai; Arno W Hoes; Jean-Yves Le Heuzey; Hercules Mavrakis; Theresa McDonagh; Jose Luis Merino; Mostapha M Nawar; Jens Cosedis Nielsen; Burkert Pieske; Lidija Poposka; Frank Ruschitzka; Michal Tendera; Isabelle C Van Gelder; Carol M Wilson
Journal:  Eur Heart J       Date:  2013-06-24       Impact factor: 29.983

4.  Incidence, predictors, and outcome of conduction disorders after transcatheter self-expandable aortic valve implantation.

Authors:  Chiara Fraccaro; Gianfranco Buja; Giuseppe Tarantini; Valeria Gasparetto; Loira Leoni; Renato Razzolini; Domenico Corrado; Raffaele Bonato; Cristina Basso; Gaetano Thiene; Gino Gerosa; Giambattista Isabella; Sabino Iliceto; Massimo Napodano
Journal:  Am J Cardiol       Date:  2011-01-19       Impact factor: 2.778

5.  TRANSFORM (Multicenter Experience With Rapid Deployment Edwards INTUITY Valve System for Aortic Valve Replacement) US clinical trial: Performance of a rapid deployment aortic valve.

Authors:  Glenn R Barnhart; Kevin D Accola; Eugene A Grossi; Y Joseph Woo; Mubashir A Mumtaz; Joseph F Sabik; Frank N Slachman; Himanshu J Patel; Michael A Borger; H Edward Garrett; Evelio Rodriguez; Patrick M McCarthy; William H Ryan; Francis G Duhay; Michael J Mack; W Randolph Chitwood
Journal:  J Thorac Cardiovasc Surg       Date:  2016-10-15       Impact factor: 5.209

6.  One-year outcomes of the Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve (TRITON) trial: a prospective multicenter study of rapid-deployment aortic valve replacement with the EDWARDS INTUITY Valve System.

Authors:  Alfred A Kocher; Günther Laufer; Axel Haverich; Malakh Shrestha; Thomas Walther; Martin Misfeld; Joerg Kempfert; Linda Gillam; Christoph Schmitz; Thorsten C Wahlers; Jens Wippermann; Friedrich W Mohr; Matthias Roth; Adalbert Skwara; Parwis Rahmanian; Dominik Wiedemann; Michael A Borger
Journal:  J Thorac Cardiovasc Surg       Date:  2012-10-08       Impact factor: 5.209

7.  Determination of risk factors for pacemaker requirement following rapid-deployment aortic valve replacement.

Authors:  Parwis B Rahmanian; Kaveh Eghbalzadeh; Süreyya Kaya; Hruy Menghesha; Stephen Gerfer; Oliver J Liakopoulos; Yeong-Hong Choi; Thorsten Wahlers
Journal:  Interact Cardiovasc Thorac Surg       Date:  2018-08-01

Review 8.  Defining left bundle branch block in the era of cardiac resynchronization therapy.

Authors:  David G Strauss; Ronald H Selvester; Galen S Wagner
Journal:  Am J Cardiol       Date:  2011-03-15       Impact factor: 2.778

9.  Permanent Pacemaker Implantation After Rapid Deployment Aortic Valve Replacement.

Authors:  Matthew A Romano; Michael Koeckert; Mubashir A Mumtaz; Frank N Slachman; Himanshu J Patel; W Randolph Chitwood; Glenn R Barnhart; Eugene A Grossi
Journal:  Ann Thorac Surg       Date:  2018-04-26       Impact factor: 4.330

10.  Early and persistent intraventricular conduction abnormalities and requirements for pacemaking after percutaneous replacement of the aortic valve.

Authors:  Nicolo Piazza; Yoshinobu Onuma; Emile Jesserun; Peter Paul Kint; Anne-Marie Maugenest; Robert H Anderson; Peter P Th de Jaegere; Patrick W Serruys
Journal:  JACC Cardiovasc Interv       Date:  2008-06       Impact factor: 11.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.